Pier Capital LLC bought a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 138,900 shares of the company’s stock, valued at approximately $5,545,000. Pier Capital LLC owned about 0.10% of Catalent at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CTLT. Advisor Group Inc. boosted its stake in shares of Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the last quarter. Stifel Financial Corp boosted its stake in Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after acquiring an additional 96 shares during the last quarter. Aperio Group LLC boosted its stake in Catalent by 0.8% during the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after acquiring an additional 190 shares during the last quarter. Capstone Asset Management Co. boosted its stake in Catalent by 2.3% during the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after acquiring an additional 230 shares during the last quarter. Finally, People s United Financial Inc. boosted its stake in Catalent by 1.9% during the 2nd quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after acquiring an additional 356 shares during the last quarter. Institutional investors own 99.49% of the company’s stock.

Several brokerages have commented on CTLT. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday. BidaskClub cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Piper Jaffray Companies raised their target price on shares of Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, November 7th. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a research note on Monday, November 6th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $44.25.

In related news, Director Uwe Roehrhoff bought 7,500 shares of Catalent stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Shares of Catalent, Inc. (NYSE CTLT) traded down $0.92 during midday trading on Tuesday, reaching $37.88. The company’s stock had a trading volume of 563,400 shares, compared to its average volume of 911,929. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The firm has a market capitalization of $5,154.95, a P/E ratio of 27.13, a price-to-earnings-growth ratio of 2.49 and a beta of 1.41. Catalent, Inc. has a 12-month low of $23.09 and a 12-month high of $43.39.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company had revenue of $543.90 million during the quarter, compared to the consensus estimate of $490.75 million. During the same quarter in the prior year, the firm posted $0.16 earnings per share. The firm’s revenue was up 23.0% compared to the same quarter last year. equities research analysts forecast that Catalent, Inc. will post 1.46 EPS for the current year.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/pier-capital-llc-buys-shares-of-138900-catalent-inc-ctlt/1745290.html.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.